A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Patients With Motor Fluctuations
Status:
Completed
Trial end date:
2021-06-15
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of IPX203 (carbidopa and levodopa) extended-release
capsules (IPX203 ER CD-LD) in comparison to immediate release (IR) CD-LD in the treatment of
CD-LD-experienced subjects with Parkinson's disease (PD) who have motor fluctuations.